

AMENDMENTS

Claims 1-199 (Canceled).

200. (Previously presented) An isolated peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said peptide selectively homes to tumor vasculature.

201. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 50 residues.

202. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 40 residues.

203. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 35 residues.

204. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 30 residues.

205. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 25 residues.

206. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 20 residues.

207. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 15 residues.

208. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 12 residues.

209. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 10 residues.

210. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 9 residues.

Application No.: 10/648,813

211. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 8 residues.

212. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 7 residues.

213. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 6 residues.

214. (Previously presented) An isolated peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said peptide selectively binds collagen.

215. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 50 residues.

216. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 40 residues.

217. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 35 residues.

218. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 30 residues.

219. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 25 residues.

220. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 20 residues.

221. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 15 residues.

222. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 12 residues.

Application No.: 10/648,813

223. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 10 residues.

224. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 9 residues.

225. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 8 residues.

226. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 7 residues.

227. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 6 residues.

228. (Previously presented) A conjugate comprising a moiety linked to a homing peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), wherein said homing peptide selectively homes to tumor vasculature.

229. (Currently amended) The conjugate of claim 228, wherein said homing ~~molecule~~ peptide selectively homes to breast tumor vasculature.

230. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 50 residues.

231. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 40 residues.

232. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 35 residues.

233. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 30 residues.

234. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 25 residues.

235. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 20 residues.

236. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 15 residues.

237. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 12 residues.

238. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 10 residues.

239. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 9 residues.

240. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 8 residues.

241. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 7 residues.

242. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 6 residues.

243. (Previously presented) The conjugate of claim 228, wherein said moiety is a therapeutic agent.

244. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a cancer chemotherapeutic agent.

245. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a cytotoxic agent.

246. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is an anti-angiogenic agent.

Application No.: 10/648,813

247. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a polypeptide.

Claim 248 (Canceled).

249. (Withdrawn – currently amended) The conjugate of claim [[243]] 228, wherein said ~~therapeutic agent moiety~~ is a small molecule.

250. (Withdrawn – currently amended) The conjugate of claim [[243]] 228, ~~which~~ wherein said moiety comprises a virus.

251. (Withdrawn) The conjugate of claim 250, wherein said virus is a phage.

252. (Currently amended) The conjugate of claim 228, comprising at least two homing ~~molecules~~ peptides that each selectively homes to tumor vasculature.

253. (Currently amended) The conjugate of claim 252, wherein said at least two homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

254. (Currently amended) The conjugate of claim 228, comprising at least ten homing ~~molecules~~ peptides that each selectively homes to tumor vasculature.

255. (Currently amended) The conjugate of claim 254, wherein said at least ten homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

256. (Currently amended) The conjugate of claim 228, comprising at least 100 homing ~~molecules~~ peptides that each selectively homes to tumor vasculature.

257. (Currently amended) The conjugate of claim 256, wherein said at least 100 homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

258. (Withdrawn – currently amended) The conjugate of claim 256, ~~which~~ wherein said moiety comprises a virus.

259. (Withdrawn) The conjugate of claim 258, wherein said virus is a phage.

260. (Previously presented) A conjugate comprising a moiety linked to a homing peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), wherein said homing peptide selectively binds collagen.

261. (Currently amended) The conjugate of claim 260, wherein said homing ~~molecule~~ peptide selectively binds non-helical collagen.

262. (Currently amended) The conjugate of claim 260, wherein said homing ~~molecule~~ peptide selectively binds collagen IV.

263. (Currently amended) The conjugate of claim 262, wherein said homing ~~molecule~~ peptide selectively binds denatured collagen IV in preference to native collagen IV.

264. (Currently amended) The conjugate of claim 262, wherein said homing ~~molecule~~ peptide selectively binds the alpha 2 chain of collagen IV.

265. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 50 residues.

266. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 40 residues.

267. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 35 residues.

268. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 30 residues.

269. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 25 residues.

270. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 20 residues.

271. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 15 residues.

272. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 12 residues.

273. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 10 residues.

274. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 9 residues.

275. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 8 residues.

276. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 7 residues.

277. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 6 residues.

278. (Previously presented) The conjugate of claim 260, wherein said moiety is a therapeutic agent.

279. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a cancer chemotherapeutic agent.

280. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a cytotoxic agent.

281. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is an anti-angiogenic agent.

282. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a polypeptide.

Claim 283 (Canceled).

284. (Withdrawn – currently amended) The conjugate of claim [[278]] 260, wherein said ~~therapeutic agent moiety~~ moiety is a small molecule.

285. (Withdrawn – currently amended) The conjugate of claim [[278]] 260, ~~which~~ wherein said moiety comprises a virus.

286. (Withdrawn) The conjugate of claim 285, wherein said virus is a phage.

287. (Currently amended) The conjugate of claim 260, comprising at least two homing ~~molecules~~ peptides that each selectively binds collagen.

288. (Currently amended) The conjugate of claim 287, wherein said at least two homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

289. (Currently amended) The conjugate of claim 260, comprising at least ten homing ~~molecules~~ peptides that each selectively binds collagen.

290. (Currently amended) The conjugate of claim 289, wherein said at least ten homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

291. (Currently amended) The conjugate of claim 260, comprising at least 100 homing ~~molecules~~ peptides that each selectively binds collagen.

292. (Currently amended) The conjugate of claim 291, wherein said at least 100 homing ~~molecules~~ peptides each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

293. (Withdrawn – currently amended) The conjugate of claim 291, ~~which~~ wherein said moiety comprises a virus.

294. (Withdrawn) The conjugate of claim 293, wherein said virus is a phage.

Application No.: 10/648,813

Claims 295-298 (Canceled).